Traub Capital Management LLC Makes New $238,000 Investment in Organon & Co. $OGN

Traub Capital Management LLC purchased a new stake in Organon & Co. (NYSE:OGN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 24,537 shares of the company’s stock, valued at approximately $238,000.

A number of other institutional investors also recently bought and sold shares of OGN. Kingsview Wealth Management LLC acquired a new stake in Organon & Co. in the 2nd quarter worth about $470,000. Cetera Investment Advisers grew its stake in shares of Organon & Co. by 7.3% in the second quarter. Cetera Investment Advisers now owns 79,191 shares of the company’s stock worth $767,000 after purchasing an additional 5,421 shares in the last quarter. Creative Planning increased its position in shares of Organon & Co. by 109.2% during the 2nd quarter. Creative Planning now owns 186,614 shares of the company’s stock valued at $1,806,000 after purchasing an additional 97,429 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Organon & Co. by 8.3% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 66,741 shares of the company’s stock valued at $646,000 after buying an additional 5,110 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in Organon & Co. by 5.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 99,075 shares of the company’s stock valued at $959,000 after purchasing an additional 5,373 shares during the period. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Organon & Co. Price Performance

Shares of NYSE:OGN opened at $7.72 on Wednesday. The firm has a market capitalization of $2.01 billion, a PE ratio of 4.02, a P/E/G ratio of 1.64 and a beta of 0.59. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. The company has a 50-day moving average price of $9.08 and a two-hundred day moving average price of $9.35. Organon & Co. has a twelve month low of $6.18 and a twelve month high of $17.23.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Monday, November 10th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.08. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. During the same period in the prior year, the business earned $1.38 earnings per share. Organon & Co. has set its FY 2025 guidance at EPS. Equities analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 11th. Investors of record on Thursday, November 20th will be given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Thursday, November 20th. Organon & Co.’s dividend payout ratio (DPR) is 4.17%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on OGN. JPMorgan Chase & Co. lowered their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 11th. Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. Morgan Stanley decreased their target price on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 11th. Finally, Piper Sandler lowered shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 target price on the stock. in a report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $12.50.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.